Evaluation of nanoparticle-mediated therapies using OncoCilAir™

Controlled and targeted delivery of nanotherapeutics represents a promising strategy for the treatment of lung cancer. OncoCilAir™ allows for translational testing of drug delivery strategies directly in human tissue.


Because of its dual component, a healthy airway epithelium combined with tumour nodules, OncoCilair™ is ideal to test simultaneously the effectiveness AND the toxicity of nanoparticles-conjugated therapies.

To learn more about Oncotheis services, please contact us